MedinCell S.A
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is… Read more
MedinCell S.A (MDCLF) - Total Liabilities
Latest total liabilities as of September 2025: $105.41 Million USD
Based on the latest financial reports, MedinCell S.A (MDCLF) has total liabilities worth $105.41 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MedinCell S.A - Total Liabilities Trend (2016–2025)
This chart illustrates how MedinCell S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MedinCell S.A Competitors by Total Liabilities
The table below lists competitors of MedinCell S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chlitina Holding Ltd
TW:4137
|
Taiwan | NT$4.27 Billion |
|
Bookook Sec
KO:001270
|
Korea | ₩5.53 Trillion |
|
Kingstone Companies Inc
NASDAQ:KINS
|
USA | $320.94 Million |
|
Lagardere SCA
PA:MMB
|
France | €8.55 Billion |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
USA | $21.30 Million |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩147.32 Billion |
|
Ningbo Joy Intelligent Logistics Technology Co.Ltd.
SHE:301198
|
China | CN¥279.12 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down MedinCell S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MedinCell S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MedinCell S.A (2016–2025)
The table below shows the annual total liabilities of MedinCell S.A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $106.82 Million | +37.35% |
| 2024-03-31 | $77.77 Million | +8.57% |
| 2023-03-31 | $71.63 Million | +24.20% |
| 2022-03-31 | $57.67 Million | +5.46% |
| 2021-03-31 | $54.69 Million | +26.41% |
| 2020-03-31 | $43.27 Million | +36.31% |
| 2019-03-31 | $31.74 Million | -14.45% |
| 2018-03-31 | $37.10 Million | +45.20% |
| 2017-03-31 | $25.55 Million | +159.47% |
| 2016-03-31 | $9.85 Million | -- |